ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY24 Earnings Guidance

by · The Cerbat Gem

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) updated its FY24 earnings guidance on Friday. The company provided EPS guidance of $4.90-5.05 for the period, compared to the consensus EPS estimate of $4.72. The company issued revenue guidance of $594-602 million, compared to the consensus revenue estimate of $590.33 million. ANI Pharmaceuticals also updated its FY 2024 guidance to 4.900-5.050 EPS.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $61.44 on Friday. The firm has a fifty day simple moving average of $58.66 and a two-hundred day simple moving average of $61.52. ANI Pharmaceuticals has a 52 week low of $48.20 and a 52 week high of $70.81. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $1.29 billion, a P/E ratio of 52.51 and a beta of 0.71.

Analysts Set New Price Targets

A number of brokerages have issued reports on ANIP. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. HC Wainwright restated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Raymond James lifted their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Finally, Piper Sandler began coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price on the stock. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $77.33.

Check Out Our Latest Stock Report on ANIP

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Read More